Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics Inc. is heading into a heavy clinical-data stretch with fresh Wall Street backing, after Stifel analyst Paul Matteis initiated coverage of the Nasdaq-listed company with a Buy rating and a $30 price target. The focus is DT120 ODT, an orally disintegrating tablet form of lysergide D-tartrate, better known as LSD, now in late-stage trials for anxiety and depression.